XML 25 R15.htm IDEA: XBRL DOCUMENT v3.25.3
Industry Segment Information
 9 Months Ended
Sep. 28, 2025
Segment Reporting [Abstract]  
Industry Segment Information Segment Information
The Company discloses information about its operating segments based on the way that management organizes the segments within the Company for making operating decisions and assessing financial performance. The Company’s chief operating decision maker (“CODM”) is the Chief Executive Officer. The CODM evaluates the performance of the Company’s operating segments based on revenue and operating income adjusted for certain items. Intersegment revenue and transfers are not significant. The accounting policies of the operating segments are the same as those described in Note 1, Nature of Operations and Accounting Policies, to the audited consolidated financial statements in the 2024 Form 10-K.
Effective at the beginning of fiscal year 2025, the Company implemented changes to its operating model. The majority of the Company’s Applied Genomics business, previously reported as part of the Diagnostics segment, has been integrated into a newly formed Life Sciences Solutions business, encompassing all Life Sciences reagents and consumables, instruments and services, as well as technology and licensing, which is reported as part of the Life Sciences segment. Beginning in fiscal year 2025, the Life Sciences segment consists of Life Sciences Solutions and Software, while the Diagnostics segment consists of Immunodiagnostics and Reproductive Health.
The effect of the change is not significant. Prior period financial information has been reclassified to reflect this new segment composition for consistent comparison.
The Company has included the expenses for its corporate headquarters, such as legal, tax, audit, human resources, information technology, and other management and compliance costs, as well as the activity related to the mark-to-market adjustment on postretirement benefit plans, as “Corporate” below. The Company has a process to allocate and recharge expenses to the reportable segments when these costs are administered or paid by the corporate headquarters based on the extent to which the segment benefited from the expenses. These amounts have been calculated in a consistent manner and are included in the Company’s calculations of segment results to internally plan and assess the performance of each segment for all purposes, including determining the compensation of the business leaders for each of the Company’s operating segments.
The primary financial measure by which the CODM evaluates the performance of the Company’s segments is adjusted operating income. Adjusted operating income consists of operating income plus amortization of intangible assets, adjustments to operations arising from purchase accounting (primarily adjustments to the fair value of acquired inventory that are subsequently recognized), acquisition and divestiture-related costs, and other costs that are not expected to recur or are of a non-cash nature, primarily including transformation costs, significant litigation matters and restructuring actions. The CODM does not evaluate operating segments using discrete asset information and there are no segment assets reported to the CODM. Accordingly, no segment assets have been reported.
Revenue and operating income, including significant segment expenses, by reportable segment are shown in the table below:  
Three Months Ended
September 28, 2025September 29, 2024
Life SciencesDiagnosticsTotalLife SciencesDiagnosticsTotal
(In thousands)
Segment revenue$342,822 $356,127 $698,949 $338,800 $345,249 $684,049 
Segment cost of revenue129,976 158,900 117,546 144,653 
Segment selling, general and administrative expenses84,190 84,719 84,944 84,116 
Segment research and development expenses27,608 23,132 25,745 22,632 
Segment operating income$101,048 $89,376 190,424 $110,565 $93,848 204,413 
Corporate expenses(8,008)(10,915)
Amortization of intangible assets(84,074)(89,642)
Purchase accounting adjustments(348)(103)
Acquisition and divestiture-related costs(284)(4,874)
Transformation costs(5,103)— 
Significant litigation matters and settlements(785)(810)
Restructuring and other, net(9,926)82 
Interest and other (expense) income, net(26,211)2,206 
Income from continuing operations before income taxes$55,685 $100,357 
Nine Months Ended
September 28, 2025September 29, 2024
Life SciencesDiagnosticsTotalLife SciencesDiagnosticsTotal
(In thousands)
Segment revenue$1,049,115 $1,034,880 $2,083,995 $1,023,839 $1,001,815 $2,025,654 
Segment cost of revenue384,325 450,130 361,534 421,836 
Segment selling, general and administrative expenses258,271 258,736 255,048 249,996 
Segment research and development expenses84,291 73,201 78,174 67,182 
Segment operating income$322,228 $252,813 575,041 $329,083 $262,801 591,884 
Corporate expenses(30,912)(33,725)
Amortization of intangible assets(252,063)(271,500)
Purchase accounting adjustments(2,349)(7,348)
Acquisition and divestiture-related costs(2,950)(22,115)
Transformation costs(6,226)— 
Significant litigation matters and settlements(12,495)(7,086)
Significant environmental matters1,208 — 
Restructuring and other, net(24,368)(22,119)
Interest and other expense, net(68,169)(6,423)
Income from continuing operations before income taxes$176,717 $221,568 
Depreciation expense included in the Company’s reportable segment operating income and corporate expenses is as follows:
Three Months EndedNine Months Ended
 September 28,
2025		September 29,
2024		September 28,
2025		September 29,
2024
 (In thousands)
Life Sciences$8,456 $8,674 $24,188 $25,068 
Diagnostics8,785 8,839 23,910 24,540 
Corporate744 516 2,100 1,708 
Total depreciation expense$17,985 $18,029 $50,198 $51,316